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ess: marc.decramer@uzSummary Chronic obstructive pulmonary disease (COPD) is characterised by a
range of pathological changes of the respiratory system, including airflow limitation
secondary to structural changes of the small airways and loss of alveolar
attachments, inflammation, ciliary dysfunction, and increased mucous production.
COPD also has significant systemic consequences. The relationships between these
pulmonary and nonpulmonary morbidities are not fully understood, and this further
complicates the assessment of disease severity and prognosis. Although improving
lung function and disease symptoms have been the main focus of COPD management,
these parameters alone do not reflect the full burden of disease. More recent
endeavours have highlighted the potential role of addressing physical limitations
imposed by systemic alterations.
It is evident that systemic manifestations are common in COPD. Indeed, many
patients demonstrate a gradual and significant weight loss that exacerbates the
course and prognosis of disease. This weight loss is often accompanied by peripheral
muscle dysfunction and weakness, which markedly contribute to exercise limitation
and impaired quality of life. Weight loss has been postulated to be the result of a
high metabolic rate that is not compensated for by increased dietary intake. The
cause of this elevated metabolism is a matter of much debate, and several factors
have been implicated. Similarly, the processes underlying depletion of muscle mass
and function have not been fully delineated.
The impact of the systemic manifestations of COPD is substantial, and although
many attempts have been made to elucidate the mechanisms underlying these
manifestations, there are important questions, which remain to be answered. AnElsevier Ltd. All rights reserved.
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therapeutic targets, and assist in guiding future therapeutic development.
& 2005 Elsevier Ltd. All rights reserved.Introduction
Chronic obstructive pulmonary disease (COPD) is a
debilitating multicomponent respiratory condition.
The pathogenesis and clinical manifestations of COPD
are not confined solely to pulmonary inflammation and
structural remodelling, but extend to and encompass a
variety of systemic alterations.1 These extrapulmonary
effects include systemic inflammation, nutritional
abnormalities and weight loss, skeletal muscle dys-
function and additional organ effects. The high burden
of COPD resulting from respiratory symptoms, such as
breathlessness and exacerbations, is further contrib-
uted to by systemic effects, leading to a pronounced
deterioration in health status and a diminished quality
of life (QoL). Recently, there has been a much greater
appreciation of the clinical importance of the systemic
manifestations of COPD.1 This article will focus
primarily on the systemic nutritional and muscular
components of COPD, discussing aetiology, diagnosis
and treatment approaches.
Nutritional abnormalities in pulmonary
disease: evidence from epidemiological
studies
The most obvious clinical expression of nutritional
abnormalities is unexplained weight loss.1 Evidence
of a relationship between body weight and COPD first
emerged from a study investigating metabolic
imbalances in severe bronchial obstruction.2 The
authors detected a meaningful correlation between
low body weight and reduced survival rates in the
participants, highlighting for the first time the role of
nutritional depletion in COPD. This observation was
later confirmed and extended, in a large population
study, in which body weight was found to be directly
related to severity of lung function determined by
the forced expiratory volume in 1 s (FEV1).
3 This
study also provided additional information on the
role of body weight on survival—mortality was found
to increase as patient body weight decreased,
regardless of lung function impairment. Low body
weight therefore appears to be an independent
marker of poor disease outcome.4
Aetiology of nutritional depletion: what, why
and how?
Several studies have shown that malnutrition or
reduced body weight is common in individuals withCOPD, affecting approximately 10–15% of patients
with mild-to-moderate disease, and 50% of patients
with advanced-stage disease and chronic respira-
tory failure.5–8 The pathophysiological basis of
weight loss is not very well understood, although
a high metabolic rate that is not compensated for
by a corresponding increase in caloric intake is
thought to play an important role.9,10 The cause of
the increased basal metabolic rate, however, is a
matter of much debate and several hypotheses
have been proposed (Fig. 1).
One hypothesis implicates increased energy
expenditure, with the increased oxygen consump-
tion by respiratory muscles that results from the
increased workload required to overcome airway
obstruction—the hallmark of COPD.11 More re-
cently, however, other studies have demonstrated
that increased oxygen consumption is also evident
in skeletal, non-respiratory muscle in COPD pa-
tients. Furthermore, breathing efficiency is com-
parable between patients with COPD, and healthy
volunteers.12 The role of the oxygen cost of
breathing in the hypermetabolic state of COPD,
therefore, remains uncertain.
Other factors implicated in raising basal meta-
bolic rate include medications commonly used in
the treatment of COPD (e.g. b2-agonists and the
phosphodiesterase inhibitor theophylline) and ca-
techolamines (e.g. noradrenaline), although stu-
dies investigating the role of these hormones in
hypermetabolism are limited. In addition, inflam-
matory mediators, such as tumour necrosis factor-
alpha (TNF-a), C-reactive protein and lipopolysac-
charide-binding protein are thought to play a
role.13 Finally, the increased thermic effect of
patient activity has also been reported to con-
tribute to the increased metabolism observed in
COPD patients.14
Assessing nutritional status: methods of
evaluation
Depletion in fat-free mass (including skeletal mus-
cle) accounts for much of the observed weight loss
in COPD, although cases have been reported in
which alterations in body composition occurred
even in the absence of any obvious weight loss.8,15,16
Several methods are employed for measuring body
composition. Anthropometry is a simple and widely
used approach for assessing fat mass through
skinfold thickness, body circumference, body mass
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Figure 1 Pathogenesis of nutritional depletion in COPD: a multicomponent disease.
Systemic effects of COPD S5index and body weight parameters, although the
assumption that the measured fat layer is repre-
sentative of total body fat may lead to an under-
estimation or overestimation of fat mass.14,17 More
sophisticated methods are used to detect subtle
changes in body composition. For example, dual-
energy X-ray absorptiometry—where a double
photon beam generated by an X-ray source is used
to distinguish between different body tissues—is a
reliable, non-invasive and easy to perform method.
However, because of cost considerations and the
need for normative reference data, this technology
is not yet widely applied to determine nutritional
depletion in COPD.14,18 On the other hand, bioelec-
trical impedance analysis (BIA) is a simple, non-
invasive and inexpensive tool for measuring nutri-
tional status in COPD. By applying a low alternating
current through electrodes attached to the wrist
and ankle, the resulting resistance provides a good
method for estimating lean body mass (LBM).19
Compared with traditional anthropometric ap-
proaches, BIA provides a more accurate evaluation
of nutritional abnormalities.20Impact of nutritional depletion on COPD
outcomes: a poor prognosis?
From a clinical viewpoint, the altered nutritional
status associated with the progressive impairment
of respiratory function in COPD poses a serious
problem and its impact on the natural course of
COPD is, therefore, of paramount importance.
To understand how nutritional depletion can
influence disease outcomes, studies have examinedthe effect of reduced body weight on exercise
tolerance,17,21 QoL7 and mortality.3,4,6,22 A com-
promised nutritional state was shown to limit
exercise performance in patients with COPD by
reducing the aerobic capacity of exercising mus-
cles.17,21 Further evidence (Del Ponte et al.,
unpublished data) in support of this effect comes
from reports of a strong correlation between 6-min
walking distance, and the quantity of metabolically
active lean body cellular mass (BCM; Fig. 2) in a
group of 50 patients with stable COPD, presenting
with FEV1 40.66710.82 (mean7SD). To assess the
impact of reduced body weight on health status
outcomes, one study has evaluated the relationship
between nutritional status and health-related
quality of life (HRQoL) using the St. George’s
Respiratory Questionnaire (SGRQ).7 It was found
that abnormally low body weight was associated
with greater impairment in health status, reflected
by low SGRQ scores. Moreover, increased dyspnoea
was the most influential predictor of HRQoL, a
respiratory symptom reported to be particularly
prevalent in underweight patients.7,23
The impact of low body weight on patients with
COPD was found to correlate with morbidity in
relation to exacerbations in a group of 68 patients
with severe, stable COPD (54 males) with chronic
respiratory failure (mean7SD PaO2: 53.776.00)
kept on long-term oxygen therapy (Fig. 3; De
Benedetto et al., unpublished data). This provided
support to observations from an earlier study, in
which malnutrition was reported to be associated
with a poor outcome following an acute exacerba-
tion in patients with respiratory failure.24 The
reduction in active cell mass in these individuals
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Figure 3 The relationship between body cell mass (BCM) and exacerbations (bacterial airway colonisation) in COPD
patients with chronic respiratory failure (De Benedetto et al., unpublished data).
Figure 2 The relationship between body cell mass (BCM) and 6-min walk distance (6MWD) in patients with stable COPD
(Del Ponte et al., unpublished data).
M. Decramer et al.S6was found to correlate with a high rate of intensive-
care-unit mortality.
In addition to the consequences of nutritional
impairment on morbidity in COPD, the effect of low
body weight on survival has been investigated.
Several epidemiological studies have demonstrated
malnutrition to be a strong predictor of mortality in
patients with COPD. Indeed, there is a strong
association between patients who experience sig-
nificant weight loss, and the risk of
death.3,4,6,22,25,26 Taken together, these data pro-vide unequivocal evidence that low body weight
exerts a negative impact on outcomes in patients
with COPD.Muscle wasting and dysfunction:
manifestations of another kind
The role of skeletal muscle dysfunction in COPD
The depletion of muscle mass and function are now
recognised as important features of COPD, con-
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prognosis. The presence of muscle dysfunction in
COPD was first recognised in a study demonstrating
that many patients with COPD have limited
exercise capacity owing to skeletal muscle fati-
gue.27 This finding challenged previous notions that
such limitations were due to dyspnoea. Conse-
quently, this observation fuelled extensive research
in the field and many studies have since confirmed
the role of skeletal muscle dysfunction in the
pathogenesis of COPD.28–30Mechanisms of skeletal muscle dysfunction
It is postulated that skeletal muscle dysfunction in
COPD arises from two complex, inter-related
events: muscle mass depletion caused by mito-
chondrial abnormalities and loss of contractile
proteins; and muscle dysfunction or malfunction
of the remaining muscle.1 The pathophysiological
mechanisms underlying skeletal muscle dysfunction
have not been fully elucidated, however, and while
nutritional imbalances have been shown to be
involved, a host of other factors have also been
implicated (Table 1).
At present, the relative contribution of each of
these components and how they interact are
unclear. Deconditioning is almost certainly an
important contributor, given that patients with
COPD have reduced physical activity, which results
in further impairment in skeletal muscle func-
tion—leading to more symptoms at lower levels of
work.31 Medications such as oral corticosteroids
also contribute to skeletal muscle dysfunction by
causing skeletal muscle myopathy, an insidious
disease leading to weakness mainly in the proximal
muscles of the lower and upper limbs. Two
different clinical patterns of steroid-induced myo-
pathy are known—an acute form, which arises
following short-term treatment with high doses of
steroids, and a common, chronic form, which
occurs after prolonged use with moderate
doses.32,33 The frequency of such events in patients
treated with relatively low doses, whether in
chronic treatment or in repetitive bursts during
exacerbations, remains unclear. Nevertheless, aTable 1 Causes of muscle weakness in COPD.
Deconditioning Systemic corticosteroids
Systemic inflammation Hypoxaemia
Oxidative stress Hypercapnia
Nutritional imbalance Electrolyte disturbances
Reduced anabolic status Cardiac failuresedentary lifestyle, which is often adopted by COPD
patients, may serve to exacerbate these effects.1
As adequate levels of anabolic hormones are
required for normal muscle growth and develop-
ment,34 reports of substantially reduced levels of
growth-promoting factors (e.g. insulin-like growth
factor-1 (IGF-1)) and sex hormones (e.g. testoster-
one) have led to suggestions that such alterations
may contribute to muscle dysfunction in COPD.35 It
is also speculated that elevated levels of systemic
proinflammatory cytokines (e.g. TNF-a and inter-
leukin-6 (IL-6)) observed in individuals with COPD
play a role in the development of peripheral muscle
weakness.15,36 Indeed, it appears that there may be
a correlation between peripheral muscle function
and inflammation during the exacerbations experi-
enced by patients with COPD.
The physiological changes that accompany ex-
acerbations are known to contribute to respiratory
muscle weakness.37 To further investigate the
contribution of these events to peripheral muscle
weakness, and specifically the impact on muscle
force, a recent study sought to define the clinical
course of quadriceps force (QF) during an acute
COPD exacerbation. Potential correlations with
systemic inflammatory markers, such as IGF-1, IL-
6, CXC chemokine ligand-8 (CXCL-8) and TNF-a in
both hospitalised and stable COPD patients, were
also defined.36 The study revealed that muscle
force was significantly reduced and subject to
alterations in patients hospitalised with COPD,
compared with patients with stable disease. More-
over, correlations between muscle force and
systemic levels of IGF-1 and CXCL-8 were demon-
strated, where QF was found to positively correlate
with IGF-1 and negatively correlate with CXCL-8 in
both hospitalised and stable COPD patients.36
Changes in peripheral muscle force in COPD, and
its relationship to systemic inflammatory markers
require further investigation.36
Tissue hypoxia, through suppression of protein
synthesis in muscle cells and alterations in struc-
tural (reduction in type I fibres) and functional
(upregulation of mitochondrial cytochrome oxi-
dase) components, as well as oxidative stress,
electrolyte imbalance and comorbid conditions
(e.g. cardiac failure), have also been implicated
in skeletal muscle dysfunction, although their
precise role remains to be fully established.
The pathophysiological mechanisms associated
with muscle weakness are complex and additional
studies will help to unravel the molecular and
biochemical pathways underlying this systemic
effect. Currently, physical inactivity is the only
convincing factor that is known to contribute to
muscle weakness in COPD.
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Whatever the cause, muscle weakness has impor-
tant consequences, including exercise limita-
tion,28,38,39 reduced QoL, enhanced utilisation of
healthcare resources40 and reduced survival.41
Traditionally, limitations in exercise performance
in COPD were attributed to dyspnoea and reduced
ventilatory capacity. However, several studies have
since demonstrated that lung function alone cannot
account for impaired exercise performance, and
that peripheral and respiratory muscle weakness
also contribute.27,29 Low exercise tolerance has a
large influence on health status in COPD30 because
physical deconditioning can lead to a marked
reduction in a patient’s ability to cope with
activities of daily living, consequently leading to a
reduction in QoL. Muscle weakness has also been
found to be related to a high utilisation of
healthcare resources.40 In fact, weak correlations
between muscle weakness and medical consump-
tion (including steroid treatment) have been noted,
although whether this relationship was causal
merits further investigation.40 Taken together,
these data show that the burden of muscle
dysfunction in COPD is significant.Pulmonary rehabilitation: interventions
aimed at improving disease outcome
Weight loss and muscle wasting have long been
considered irreversible events. However, several
reports in the literature describe the efforts that
have been made in finding effective approaches to
overcoming nutritional abnormalities and improv-
ing muscle function. Pulmonary rehabilitation
programmes have been developed and implemen-
ted in COPD patients, with the primary aim of
increasing exercise tolerance and improving quality
of life. Key components of these programmes
include exercise and muscle training and nutri-
tional supplementation.Management of malnutrition: assessing the role
of nutritional supplementation
The rationale for treatment interventions aimed at
increasing body weight is based on the observed
relationship between weight loss, muscle wasting
and muscle weakness.6 Indeed, several studies
have demonstrated that restoration of energy
balance through nutritional supplementation re-
sults in a significant increase in body weight, fat-
free mass and respiratory muscle function.10,42–44
However, other studies failed to demonstrate such
benefits following nutritional repletion.45,46 To
clarify the effect of nutritional support, a meta-analysis of numerous randomised controlled trials
was conducted,5 which revealed small, insignificant
effects on anthropometric measures, lung function
or functional exercise capacity among patients with
COPD. These data are thus inconclusive, high-
lighting the need for additional studies using
homogeneous populations of COPD patients who
are selected for the same physical characteristics
and severity of bronchial obstruction, in order to
fully understand the merits of nutritional support.
Management of muscle dysfunction: assessing the
role of exercise training
Given the contribution of peripheral and respira-
tory muscle weakness to exercise limitation,
muscle training is an integral component of
rehabilitation programmes.28 Indeed, exercise
training has been shown to improve exercise
capacity in COPD patients.47,48 Moreover, training
has been shown to induce a partial improvement in
oxidative capacity and exercise performance in
peripheral muscles.30 However, other studies re-
vealed how a large fraction of patients (more than
a third) failed to respond to a training pro-
gramme.49 Whether or not patients respond to a
training programme may be related to levels of
circulating cytokines,50 but further characterisa-
tion of non-responders is required to determine the
mechanisms underlying the absence of response.Conclusions
This review underlines the role of systemic effects
in the pathogenesis of COPD. Whilst tremendous
progress has been made in defining the clinical
implications of nutritional abnormalities and mus-
cle dysfunction, further studies are required to gain
a better understanding of the pathophysiological
mechanisms giving rise to these effects. Resolving
the complex systemic nature may allow current
therapeutic approaches to be optimised and novel
intervention strategies to be identified, leading to
improvements in functionality, health status and
prognosis of patients living with COPD.References
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